George Medicines Taps Korean Partner in Global Hypertension Drug Rollout

LONDON, UK – March 11, 2026 – George Medicines, a biopharmaceutical firm with roots in academic global health research, has inked an exclusive licensing agreement with Ahngook Pharmaceutical to bring its innovative hypertension treatment, GMRx2, to the South Korean market. The deal marks the company's fifth major international partnership, solidifying a global commercialization strategy that hinges on leveraging local expertise to tackle one of the world's most pervasive chronic diseases.

Under the terms of the agreement, Seoul-based Ahngook Pharmaceutical gains the exclusive rights to pursue regulatory approval and commercialize GMRx2 in Korea. In return, George Medicines will receive an upfront fee, future payments tied to regulatory and sales milestones, and a recurring revenue stream from stepped royalties. This partnership follows a series of similar deals in the United States, Canada, Latin America, and Southeast Asia, painting a clear picture of a company executing a deliberate, market-by-market global expansion.

A Global Playbook Validated

The Korean agreement is more than just another pin on the map for George Medicines; it's a continuation of a successful global playbook. The company’s strategy involves identifying strong regional partners with established commercial infrastructure and regulatory know-how to navigate complex local markets. This model allows the late-stage biopharma company to focus on its core strengths—drug development and clinical research—while ensuring its products have a clear path to patients worldwide.

This strategy recently received its most significant validation in the United States. GMRx2, branded as WIDAPLIK™ in the US, secured FDA approval in June 2025. Critically, it became the first and only triple-combination therapy approved for initial treatment in adults with hypertension, a landmark achievement that sets it apart in a crowded therapeutic area. The successful US regulatory journey, which included a New Drug Application submitted in August 2024, provides a powerful precedent and a robust data package that will support Ahngook Pharm’s regulatory submission in Korea.

Mark Mallon, Chief Executive Officer of George Medicines, commented on the partnership's strategic fit, stating, “In Ahngook Pharmaceutical we have a strong commercial partner who shares our belief in the potential of GMRx2 to help address key challenges in current hypertension treatment approaches. Through our partnership we have an opportunity to advance cardiovascular care, and we look forward to working with the team to support GMRx2’s regulatory approval in Korea.”

A New Weapon in Korea's Fight Against Hypertension

The introduction of GMRx2 is poised to address a significant public health challenge in South Korea. Hypertension affects nearly a third of Korean adults over 30, a prevalence that is steadily rising. The condition is a major risk factor for stroke, which has a particularly strong association with blood pressure in Asian populations. Furthermore, factors like high sodium diets contribute to a high rate of salt-sensitive hypertension, creating a need for highly effective and well-tolerated treatment options.

Korean clinical guidelines already favor the use of single-pill combination therapies to improve patient adherence and clinical outcomes. GMRx2 fits perfectly into this paradigm. By combining three distinct and proven medicines—telmisartan, amlodipine, and indapamide—in a single daily tablet, it simplifies treatment regimens, a crucial factor in managing a lifelong condition like hypertension. Poor adherence is a primary reason for uncontrolled blood pressure, and a single-pill solution is a proven method to overcome this barrier.

Park In-choul, Chief Executive Officer of Ahngook Pharmaceutical, highlighted the clinical need, saying, “This agreement expands our cardiovascular portfolio and signals our continued commitment to improve outcomes for patients. We look forward to working with George Medicines to bring this important treatment option to patients in Korea.”

The Science Behind the Single Pill

GMRx2’s potential is underpinned by a wealth of rigorous clinical data. Its development program includes two pivotal Phase III studies published in prestigious medical journals, The Lancet and the Journal of the American College of Cardiology. These trials demonstrated that the triple combination therapy significantly reduced blood pressure and improved control rates when compared directly against dual-therapy combinations, all while maintaining a favorable safety profile with no increase in treatment withdrawals due to side effects.

The therapy’s multi-mechanism approach is key to its efficacy. It combines an angiotensin II receptor blocker (telmisartan), a calcium channel blocker (amlodipine), and a thiazide-like diuretic (indapamide). This synergy allows for powerful blood pressure reduction, often at lower doses of each individual component, which can minimize dose-related side effects. The availability of GMRx2 in multiple dose strengths, including formulations with lower doses than other available combinations, gives clinicians greater flexibility to tailor treatment to individual patient needs from the outset.

Further evidence comes from the VERONICA trial in Nigeria, which showed GMRx2 was superior to a standard-of-care protocol in lowering blood pressure among patients with uncontrolled hypertension, achieving over 80% control rates within a month.

From Research Lab to Global Market

The story of GMRx2 is also the story of George Medicines itself—a unique entity born from a desire to translate world-class academic research into tangible global health solutions. The company is an independent spin-out from The George Institute for Global Health, a leading medical research institute focused on addressing global health inequity. This origin instills a mission-driven purpose into its commercial activities.

Backed by Brandon Capital, Australia’s leading life sciences venture firm, and George Health, the commercial arm of The George Institute, the company embodies a modern model for biotech innovation. It bridges the gap between the lab and the patient by commercializing therapies designed not just for developed markets, but for global accessibility. The ongoing global trial investigating GMRx2 for the prevention of stroke in people who have had an intracerebral hemorrhage further underscores its commitment to addressing the most severe consequences of cardiovascular disease. The strategic partnership with Ahngook Pharmaceutical is the latest chapter in this story, extending the reach of this promising therapy to a market with a clear and pressing medical need.